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ABSTRACT
The envelope glycoprotein of human immunodefi-
ciency virus (HIV) consists of an exterior glycopro-
tein (gp120) and a trans-membrane domain (gp41)
and has an important role in viral entry into cells.
HIV-1 entry has been validated as a clinically rele-
vant anti-viral strategy for drug discovery. In the
present work, several 2’-F substituted RNA apta-
mers that bind to the HIV-1BaL gp120 protein with
nanomole affinity were isolated from a RNA library
by the SELEX (Systematic Evolution of Ligands by
EXponential enrichment) procedure. From two of
these aptamers we created a series of new dual
inhibitory function anti-gp120 aptamer–siRNA chi-
meras. The aptamers and aptamer–siRNA chimeras
specifically bind to and are internalized into cells
expressing HIV gp160. The Dicer-substrate siRNA
delivered by the aptamers is functionally processed
by Dicer, resulting in specific inhibition of HIV-1
replication and infectivity in cultured CEM T-cells
and primary blood mononuclear cells (PBMCs).
Moreover, we have introduced a ‘sticky’ sequence
onto a chemically synthesized aptamer which facil-
itates attachment of the Dicer substrate siRNAs for
potential multiplexing. Our results provide a set of
novel inhibitory agents for blocking HIV replication
and further validate the use of aptamers for delivery
of Dicer substrate siRNAs.
INTRODUCTION
The global epidemic of infection by HIV has created
an urgent need for new classes of antiretroviral agents.
HIV-1 infection is initiated by the interactions between
the external envelope glycoprotein gp120 of HIV and the
human cell surface receptor CD4 (1–4), subsequently lead-
ing to fusion of the viral membrane with the target cell
membrane (5,6). Thus, HIV-1 entry into its target cells
represents an attractive target for new anti-HIV-1 drug
development (7–12).
The most eﬀective anti-HIV drugs used in the clinic
consist of combinations of compounds that block the
early reverse transcription step, and the late viral gag pro-
tein maturation step (13–15). Preventing the virus from
binding to its primary receptor is one of the most obvious
and direct ways to prevent infection. One rational antiviral
approach is to create some small ligands directed to
the virus surface protein gp120. Successes in discovering
new classes of gp120-directed inhibitors targeted to the
initial step of HIV-1 entry have been reported in recent
years (8,16,17). Soluble CD4 (sCD4) has demonstrated
eﬃcacy against many laboratory strains (18,19), however
disappointing results from clinical trials were attributed
to poor activity of this drug against primary isolates
(20,21). Another entry inhibitor PRO-542, a CD4-IgG
recombinant fusion protein eﬀectively neutralizes many
HIV-1 strains in cell culture (22,23) as well as clinical iso-
lates (24,25), but unfortunately this drug has not enjoyed
widespread use in the clinical treatment of HIV infection.
Other inhibitors bind gp120 less speciﬁcally through elec-
trostatic or lectin–carbohydrate interactions [sulfated
polymers, cyanovirin (26)]. These properties create
challenges for the practical implementation of these mole-
cules as drugs. In 2003, Martin et al. (27) designed a 27-aa
CD4 peptide mimic, CD4M33, which was shown to bind
to gp120 and inhibit HIV-1 infection in vitro. The clinical
application of this peptide though has not yet taken
place. Aside from antibody or peptide mimics, nucleic
acid aptamers with low to mid-range nanomole binding
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(27–30). Aptamers which block the interaction of
gp120 and CD4 have been previously developed. One
such aptamer was shown to speciﬁcally interact with
the conserved coreceptor interacting region of R5 strain
gp120 (29).
Although both aptamers and antibody or engineered
peptide mimics have great speciﬁcity and binding aﬃnity,
the nucleic acid-based aptamers oﬀer more synthetic
accessibility, convenient modiﬁcation, chemical versatility,
stability and lack immunogenicity (31). Therefore,
aptamers can be utilized for ﬂexible applications ranging
from diagnostic to therapeutic assay formats (32,33).
Aptamers that target speciﬁc cell surface proteins are
employed as interesting delivery molecules to target a
distinct cell type, hence reducing oﬀ-target eﬀects or
other unwanted side eﬀects. The ﬁrst example of aptamers
used for siRNA delivery is an anti-PSMA aptamer (34)
that binds tightly to the prostate-speciﬁc membrane anti-
gen (PSMA), a prostate cancer cell-surface receptor.
McNamara et al. (35) in 2006 reported the use of this
aptamer for receptor mediated siRNA delivery. In this
study, they selectively delivered a 21-mer siRNA into
PSMA expressing cells, resulting in silencing of target
transcripts both in cell culture and in vivo following
intra-tumoral delivery. Similarly, Chu et al. (36) used a
modular streptavidin bridge to connect lamin A/C or
GAPDH siRNAs to the biotinylated variants of this
anti-PSMA aptamer. Consequently, this system induced
silencing of the targeted genes only in cells expressing
the PSMA receptor. The targeting properties of the anti-
PSMA aptamer also can be exploited for localizing
other therapeutic agents to tumors such as a toxin (37),
doxorubicin (38) or nanoparticles (39–42). We recently
described a novel dual inhibitory function anti-gp120
aptamer-siRNA chimera, in which both the aptamer and
the siRNA portions have potent anti-HIV activities (43).
Additionally, HIV gp120 expressed on the surface of HIV
infected cells was used for aptamer-mediated delivery of
an anti-HIV siRNA, resulting in pronounced inhibition
of HIV replication in cell culture.
For treatment of HIV using aptamer–siRNA chimeras,
it is highly desirable to generate new aptamers to
expand the diversity of target recognition for potential
use in vivo. New anti-gp120 aptamers and various
siRNAs targeting diﬀerent genes could be combined to
avert viral resistance to a single aptamer–siRNA combina-
tion. In the present study we successfully isolated sev-
eral new 20-F substituted RNA aptamers that bind to
the HIV-1Ba-L gp120 protein. Two diﬀerent types of dual
inhibitory function anti-gp120 aptamer–siRNA conju-
gates were constructed. One of these is a covalent apta-
mer–siRNA chimera and the other is an aptamer with
a GC-rich bridge that facilitates the interchange of diﬀer-
ent RNAs with the same aptamer. Although the aptamer
alone provided HIV inhibitory function, the aptamer–
siRNA chimeras provided more potent inhibition of
HIV suggesting cooperativity between the siRNA and
aptamer portions in inhibiting HIV replication and
spread. Our results demonstrate that our selected apta-
mers not only provide lead inhibitors for potential anti-
HIV therapeutic applications, but also act as eﬀective
delivery vehicles for anti-HIV siRNAs into HIV infected
cells. The aptamers studies here could also selectively deli-
ver other small HIV inhibitory agents.
MATERIALS AND METHODS
Materials
Unless otherwise noted, all chemicals were purchased
from Sigma-Aldrich, all restriction enzymes were
obtained from New England BioLabs (NEB) and all
cell culture products were purchased from GIBOC
(Gibco BRL/Life Technologies, a division of Invitrogen).
Sources for the other reagents were: DuraScribe T7 tran-
scription Kit (EPICENTRE Biotechnologies); Silencer
siRNA Labeling Kit (Ambion); Hoechst 33342 (nuclear
dye for live cells) (Molecular Probes, Invitrogen);
Random primers (Invitrogen); Bio-Spin 30 Columns
(Bio-Rad); Recombinant Human Dicer Enzyme Kit
(Ambion); Lipofectamine 2000 (Invitrogen); CHO-Env
Transfectants (CHO-WT and CHO-EE), the HIV-1BaL
gp120 protein and HIV-1BaL virus were obtained from
the AIDS Research and Reference Reagent Program.
siRNAs
siRNAs and antisense strand RNAs were purchased from
Integrated DNA Technologies (IDT).
Generation of aptamer and chimera RNAs by
in vitro transcription
Aptamer and chimera RNAs were prepared as previously
described (43). The sense strands of the chimeras are
underlined. The italic UU is the linker between the apta-
mer and siRNA portions.
A-1 aptamer: 50-GGGAGGACGAUGCGGAAUUGAG
GGACCACGCGCUGCUUGUUGUGAUAAGC
AGUUUGUCGUGAUGGCAGACGACUCGCC
CGA-30
B-68 aptamer: 50-GGGAGGACGAUGCGGACAUAG
UAAUGACACGGAGGAUGGAGAAAAAACA
GCCAUCUCUUGACGGUCAGACGACUCGCC
CGA-30
Chimera A-1-sense strand: 50-GGGAGGACGAUGCGG
AAUUGAGGGACCACGCGCUGCUUGUUGU
GAUAAGCAGUUUGUCGUGAUGGCAGACG
ACUCGCCCGA UU GCGGAGACAGCGACGA
AGAGCUCAUCA-30
Chimera B-68-sense strand: 50-GGGAGGACGAUGCG
GACAUAGUAAUGACACGGAGGAUGGAGA
AAAAACAGCCAUCUCUUGACGGUCAGACG
ACUCGCCCGA UU GCGGAGACAGCGACGA
AGAGCUCAUCA-30
Nucleic Acids Research,2009, Vol.37, No. 9 3095Antisense strand: 50-UGAUGAGCUCUUCGUCGCUG
UCUCCGCdTdT-30
Aptamer-Stick-siRNA
A-1-stick, Stick-sense and stick-antisense were chemically
synthesized by the Synthetic and Biopolymer Chemistry
Core in the City of Hope (the details shown in the
Supplementary Material). The A-1-stick RNA was
refolded in HBS buﬀer (10mM HEPES pH 7.4, 150mM
NaCl, 1mM CaCl2, 1mM MgCl2, 2.7mM KCl), heated
to 958C for 3min and then slowly cooled to 378C. The
incubation was continued at 378C for 10min. The Sense-
stick or Antisense-stick strand was annealed to the
complementary partner using the same molar amounts
as the corresponding partner strand to form the stick-
siRNAs (NS-1 and NS-2). The same amount of the
refolded A-1-stick was added and incubated at 378C
for 10min in HBS buﬀer to form the A-1-stick-siRNA
(N-1 and N-2).
A-1-stick: 50-GGGAGGACGAUGCGGAAUUGAGGG
ACCACGCGCUGCUUGUUGUGAUAAGCAGU
UUGUCGUGAUGGCAGACGACUCGCCCGA
XXXXXXX GUACAUUCUAGAUAGCC-30
Tat/rev N-1:
Antisense-Stick: 50-UGAUGAGCUCUUCGUCGCUG
UCUCCGC XXXXX GGCUAUCUAGAAUGUA
C-30
Sense strand: 50-GCGGAGACAGCGACGAAGAGCUC
AUCAUU-30
Tat/rev N-2:
Stick-sense: 50-GCGGAGACAGCGACGAAGAGCUC
AUCA XXXXX GGCUAUCUAGAAUGUAC-30
Antisense strand: 50-UGAUGAGCUCUUCGUCGCUG
UCUCCGCUU-30
TNPO3N-1:
Antisense-stick: 50-UACACGAGCUGCAAUGUCGG
CUUUGCU XXXXX GGCUAUCUAGAAUGUA
C -30
Sense stand: 50-CAAAGCCGACAUUGCAGCUCGUG
UAUU-30
CD4N-2:
Stick-sense: 50-UCAAGAGACUCCUCAGUGAGAAG
AA XXXXX GGCUAUCUAGAAUGUAC-30
Antisense strand: 50-UUCUUCUCACUGAGGAGUCU
CUUGAUU-30
The bold nucleotides indicate 20-Flourine modiﬁed
sugars. The stick portion is underlined. This contains
20-OMe modiﬁed A and G and 20-F modiﬁed U and C.
The italic X indicates the three-carbon linker (C3) between
the aptamer/siRNA and stick sequences.
Preparation of the RNA library
The starting DNA library contained 50 nucleotides of
random sequences and was synthesized by Integrated
DNA Technologies (Coralville, Iowa). The random
region is ﬂanked by constant regions, which include
the T7 promoter for in vitro transcription and a 30 tag
for RT–PCR. The 50 and 30 constant sequences are
50-TAA TAC GAC TCA CTA TAG GGA GGA CGA
TGC GG-30 (32-mer) and 50-TCG GGC GAG TCG TCT
G-30 (16-mer), respectively. The DNA random library
(0.4mM) was ampliﬁed by PCR using 3mM each of 50-
and 30-primers, along with 2mM MgCl2 and 200mMo f
each dNTP. In order to preserve the abundance of the
original DNA library, PCR was limited to 10 cycles.
After the PCR reactions (10 reactions, 100ml per reaction),
the ampliﬁed dsDNA pool was recovered using a
QIAquick Gel puriﬁcation Kit. The resulting dsDNA
was converted to an RNA library using the
DuraScription Kit (Epicentre, Madison, WI, USA)
according to the manufacturer’s instructions. In the
transcription reaction mixture, CTP and UTP were
replaced with 20-F-CTP and 20-F-UTP to produce ribo-
nuclease resistant RNA. The reactions were incubated
at 378C for 6h, and subsequently the template DNA
was removed by DNase I digestion. The transcribed
RNA pool was puriﬁed in an 8% polyacrylamide/7M
urea gel. The puriﬁed RNA library was quantiﬁed by
UV spectrophotometry.
In vitro selection of RNA aptamers
The SELEX was performed principally as described by
Tuerk and Gold (44). In every round, the RNA pools
were refolded in HBS buﬀer (10mM HEPES pH 7.4,
150mM NaCl, 1mM CaCl2, 1mM MgCl2, 2.7mM
KCl), heated to 958C for 3min and then slowly cooled
to 378C. Incubation was continued at 378C for 10min.
Generally, in order to minimize nonspeciﬁc binding
with the nitrocellulose ﬁlters, the refolded RNA pools
were preadsorbed to a nitrocellulose ﬁlter (HAWP ﬁlter,
0.45mm) for 30min, prior to incubation with the HIV-1Bal
gp120 protein. The precleared RNA pool was incubated
with the target protein in low-salt RNA binding buﬀer
(10mM HEPES pH 7.4, 50mM NaCl, 1mM CaCl2,
1mM MgCl2, 2.7mM KCl, 10mM DTT, 0.01% BSA
and tRNA) for 30min for SELEX rounds 1 to 4. After
the fourth round of SELEX, a high-salt RNA binding
buﬀer (10mM HEPES pH 7.4, 150mM NaCl, 1mM
CaCl2, 1mM MgCl2, 2.7mM KCl, 10mM DTT, 0.01%
BSA and tRNA) was used. With the SELEX progress, the
amount of gp120 protein was reduced and competitor
tRNA was increased in order to increase the stringency
of aptamer selection.
For the ﬁrst cycle of selection, the precleared random
RNA pool (40mg, 1.5nmol, 9 10
14 molecules) and
HIV-1Bal gp120 protein (0.23nmol, RNA/Protein ratio
6.5/1) were incubated in 200ml low-salt RNA binding
buﬀer on a rotating platform at room temperature for
30min. The reaction was passed through a prewetted
nitrocellulose ﬁlter and washed with 1ml binding buﬀer.
The bound RNA was eluted from the ﬁlter with 200ml
elution buﬀer (7M urea and 5mM EDTA) at 958C
for 5min, followed by phenol/chloroform extraction
and concentration with a Microcon YM-30 column.
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the ThermoScript RT-PCR system (Invitrogen) and
ampliﬁed for 15 cycles of PCR. After the ampliﬁed
dsDNA pool was puriﬁed using a QIAquick Gel puriﬁ-
cation Kit, it was transcribed as described above for the
next round of selection.
After 12 rounds of SELEX, the resulting cDNA was
ampliﬁed by PCR cloned into the TA cloning vector
pCR 2.1 (Invitrogen). Individual clones were identiﬁed
by DNA sequencing.
Gel shift assays and determination of dissociation constants
The gp120 protein was serially diluted to the desired
concentrations (0–640nM). A constant amount of
P
32-end-labeled RNA (10nM) was used. The binding reac-
tion was performed as described above. After incubation,
20ml of binding reaction was loaded into a 5% nondena-
turing polyacrylamide gel. Following electrophoresis
the gel was exposed to a Phosphor image screen and the
radioactivity was quantiﬁed using a Typhoon scanner.
The dissociation constants were calculated using non-
linear curve regression with a Graph Pad Prism.
Cell culture
HEK 293 cells and CEM cells were purchased from ATCC
and cultured in DMEM and RPMI 1640 supplemented
with 10% FBS. CHO-WT and CHO-EE cells were
obtained through the AIDS Research and Reference
Reagent Program and were grown in GMEM-S. Cells
were cultured in a humidiﬁed 5% CO2 incubator at 378C.
PBMCs. Peripheral blood mononuclear samples were
obtained from healthy donors from the City of hope
National Medical Center. PBMCs were isolated from
whole blood by centrifugation through a Ficoll-
Hypaque solution (Histopaque-1077, Sigma). CD8 cells
(T-cytotoxic/suppressor cells) were depleted from the
PBMCs by CD8 Dynabeads (Invitrogen, CA) according
to the manufacturer’s instructions. CD8
+ T cell-depleted
PBMCs were washed twice in PBS and resuspended in
culture media (RPMI 1640 with 10% FBS, 1 (PenStrep
and 100U/ml interleukin-2). Cells were cultured in a
humidiﬁed 5% CO2 incubator at 378C.
Cell-surface binding of experimental RNAs
(Flow cytometry analysis)
CHO-WT gp160 or CHO-EE cells were washed with
PBS, trypsinized and detached from the plates. After
washing cells twice with 500ml binding buﬀer. Cell pellets
were resuspended in binding buﬀer and incubated at
378C for 30min. Cells were then pelleted and resuspended
in 50ml of prewarmed binding buﬀer containing 400nM
Cy3-labeled experimental RNAs. After incubation at 378C
for 40min, cells were washed three times with 500mlo f
prewarmed binding buﬀer, and ﬁnally resuspended in
350ml of binding buﬀer prewarmed to 378C and analyzed
by ﬂow cytometry. For the aptamer–stick–siRNA
(N-1 and N-2), the Cy3-labeled aptamer–stick was incu-
bated with the siRNA–stick to form the aptamer–stick–
siRNA complex and the complexes were analyzed by ﬂow
cytometry.
Internalization and intracellular localization studies
(Live-cell Confocal Microscopy analyses)
The CHO-WT gp160 and CHO-EE cells were grown in
35mm plate (Glass Bottom Dish, MatTek, Ashland, MA,
USA) with seeding at 0.3 10
6 in GMEM-S medium to
allow about 70% conﬂuence in 24h. On the day of the
experiments, cells were washed with 1ml of prewarmed
PBS, and incubated with 1ml of prewarmed complete
growth medium for 30min at 378C.
Assay 1. The cells were ﬁrst stained by treatment with
0.15mg/ml Hoechst 33342 (nuclear dye for live cells,
Molecular Probes, Invitrogen, CA, USA) according to
the manufacturer’s instructions. Subsequently, Cy3-
labeled RNAs at a 100nM ﬁnal concentration were
added into the media and incubated for live-cell confocal
microscopy in a 5% CO2 microscopy incubator at 378C.
The images were collected every 15min using a Zeiss
LSM 510 Meta Inverted 2 photon confocal microscope
system under water immersion at 40  magniﬁcation.
Assay 2. Cy3-labeled RNAs at a 100nM ﬁnal concen-
tration were added to media and incubated for live-cell
confocal microscopy in a 5% CO2 microscopy incubator
at 378C. The images were collected every 15min using
a Zeiss LSM 510 Meta Inverted 2 photon confocal micros-
copy system under water immersion at 40  magniﬁcation.
After 16h of incubation and imaging, the cells were
stained by treatment with 0.15mg/ml Hoechst 33342
(nuclear dye for live cells, Molecular Probes, Invitrogen,
CA, USA) according to the manufacturer’s instructions.
The images were collected as described previously.
HIV-1 challenge and p24 antigen assays
CEM cells or human PBMCs were infected with HIV IIIB
or NL4-3 or Bal for 5 days (MOI 0.001 or 0.005). Prior to
RNA treatments the infected cells were gently washed
with PBS three times to remove free virus. Next, 2 10
4
infected cells and 3 10
4 uninfected cells were incubated
with refolded RNAs at 400nM ﬁnal concentration in
96-well plates at 378C. The culture supernatants were
collected at diﬀerent times (3d, 5d, 7d and 9d or 11d).
The p24 antigen analyses were performed using a Coulter
HIV-1 p24 Antigen Assay (Beckman Coulter) according
to the manufacturer’s instructions.
qRT–PCR analysis
As previously described, the CEM cells or human PBMCs
were infected with virus for 5 days. Prior to analyses, the
infected cells were gently washed 3 times to eliminate
free virus. The infected cells were treated directly with
the experimental RNA (400nM). After 7 days of incuba-
tion, total RNAs were isolated with STAT-60 (TEL-TEST
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coding RNAs was analyzed by quantitative RT–PCR
using 2(iQ SyberGreen Mastermix (BIO-RAD) and spe-
ciﬁc primer sets at a ﬁnal concentration of 400nM. Primers
were as follows: IIIB and NL4-3 tat/rev forward primer:
50-GGC GTT ACT CGA CAG AGG AG-30; IIIB and
NL4-3 tat/rev reverse primer: 50-TGC TTT GAT AGA
GAA GCT TGA TG-30; Bal tat/rev forward primer:
50-GAA GCA TCC AGG AAG TCA GC-30; Bal tat/rev
Reverse primer: 50-TGC TTT GAT AGA GAA ACT TGA
TGA-30; CD4 forward primer: 50-GCT GGA ATC CAA
CAT CAA GG-30; CD4 reverse primer: 50-CTT CTG AAA
CCG GTG AGG AC-30. TNPO3 Forward primer: 50-CCT
GGA AGG GAT GTG TGC-30; TNPO3 Reverse primer:
50-AAA AAG GCA AAG AAG TCA CAT CA-30;
GAPDH forward primer 1: 50-CAT TGA CCT CAA
CTA CAT G-30; GAPDH reverse primer 2: 50-TCT CCA
TGG TGG TGA AGA C-30.
RNA-Stat60 was used to extract total RNA according
to the manufacturer’s instructions (Tel-Test). Residual
DNA was digested using the DNA-free kit per the manu-
facturer’s instructions (Ambion, CA, USA). cDNA was
produced using 2mg of total RNA Moloney murine leuke-
mia virus reverse transcriptase and random primers in a
15ml reaction according to the manufacturer’s instructions
(Invitrogen). GAPDH expression was used for normal-
ization of the qPCR data.
In vitro Dicer assays
The sense or antisense strands were end-labeled with T4
polynucleotide kinase and g-
32P-ATP. Subsequently, cor-
responding antisense or sense strands were annealed
with equimolar amounts of 50-end-labeled sense or anti-
sense strands in HBS buﬀer to form the chimeras. The
annealed stick–siRNA was incubated with refolded
A-1-stick at 378C for 10min. The experimental RNAs
(1pmol) were incubated at 378C for 40min in the presence
or in the absence of 1U of human recombinant Dicer
enzyme following the manufacturer’s recommendations
(Ambion, Austin, TX, USA). Reactions were stopped
by phenol/chloroform extraction and the resulting
solutions were electrophoresed in a denaturing 20% poly-
acrylamide gel. The gels were subsequently exposed to
X-ray ﬁlm.
RESULTS
Selection and identification of RNA aptamers
against HIV-1BaL gp120
An in vitro SELEX procedure (44–47) was used to select
20-ﬂuoropyrimidine modiﬁed RNA aptamers which
selectively bind the R5 strain HIV-1BaL gp120 envelope
protein. To carry out the SELEX an RNA library contain-
ing a central stretch of 50 random nucleotides was
synthesized by in vitro T7 transcription. Prior to selec-
tion for binding to the gp120 protein, the initial random-
ized RNA pool, which contained 10
15 unique RNA
molecules (1.5nmol), was preadsorbed to a nitrocellulose
membrane to remove nonspeciﬁc binders. The pre-cleared
RNA pool was then incubated with 0.23nmol of
HIV-1BaL gp120 protein at room temperature. Subse-
quently, the RNA/protein complexes were isolated from
the unbound RNA molecules via binding to a nitrocellu-
lose ﬁlter. The selected RNAs were recovered from the
ﬁlter, reverse transcribed and the cDNA was ampliﬁed
by PCR. Transcripts of the PCR product were used for
the next round of selection. The ﬁlter binding assay was
used to monitor the progress of selection after each
SELEX cycle. The binding aﬃnity was evaluated as the
percent of the RNA retained on the ﬁlter in the total RNA
pool. When compared with the starting RNA pool
(1-RNA) from which 0.1% of the input RNAs were
retained on the membrane, the ninth RNA library
(9-RNA) had 9.72% of the input RNA bound. No fur-
ther enrichment was seen following additional selection
rounds (Supplementary Figure S1), suggesting that max-
imal binding of the RNA pool had been reached. The
binding activities of the RNA pools were further con-
ﬁrmed by gel shift assays (data not shown). These results
indicated that the RNA pool was successively enriched
in ligands with high binding speciﬁcity for the target
protein.
The highly enriched aptamer pools (12-RNA) were
cloned and sequenced. The individual clones were classi-
ﬁed into six diﬀerent groups based on the alignments
of individual aptamer sequences (Table 1). About forty
percent of the clones (Group I and II aptamers) included
a conserved sequence, which is comprised of 13 nucleo-
tides A(A/G)TTGAGGGACC(A/G). No common sec-
ondary structural motifs in the six groups were found
using secondary structure predictions based upon the
RNA folding algorithms Mfold and Quickfold. One rep-
resentative sequence from each group (A-1, A-5, A-9,
A-12, A-28 and B-68) was chosen for further characteriza-
tion because of their relative abundance within their
group. The dissociation constants (Kd) for selected
aptamers with the target protein were calculated from a
native gel mobility shift assay (Figure 1A). Three of the
aptamers showed good binding kinetics to gp120. The
apparent Kd values of A-1 and B-68 were about 52nM
and 97nM (Figure 1B and Supplementary Figure S2),
respectively. The ﬁlter binding assay (data not shown)
also conﬁrmed the binding activity of these individual
aptamers. These aptamers also showed selective binding
with the HIV-1BaL gp120 (data not shown) versus the
HIV gp120 CM protein.
For the sake of comparison, a 20-F modiﬁed RNA
aptamer B40t77 that is speciﬁc for the conserved
co-receptor region of the gp120 of the R5 strain of HIV-1
previously developed (28) by the James’ lab was also tested
in the gel shift assays using the HIV-1BaL gp120 protein.
Interestingly, the B40t77 aptamer did not show binding
aﬃnity to this target protein (data not shown), suggesting
that B40t77 and our selected aptamers recognize dif-
ferent epitopes of the HIV-1BaL gp120 protein. Since the
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from these studies are from diﬀerent sources, this may
explain their diﬀerent binding aﬃnities for gp120.
Anti-gp120 aptamer specifically binds and is internalized
by cells expressing HIV gp160
CHO-gp160 cells stably expressing the HIV envelope
glycoprotein gp160 were used to test for binding and inter-
nalization of the selected anti-gp120 aptamers. These
cells do not process gp160 into gp120 and gp41 since
they lack the gag encoded proteases required for envelope
processing. As a control we used the parental CHO-EE
cell line, which does not express gp160. The anti-gp120
aptamer and the truncated A-1 aptamers were labeled
with Cy3 to follow their binding and uptake. Flow cyto-
metric analyses (Figure 2A) revealed that the aptamers
speciﬁcally bound to the CHO-gp160 cells but did not
bind to the control CHO-EE cells.
In order to determine if the bound aptamers were
internalized in the gp160 expressing cells, we carried out
real-time live-cell Z-axis confocal microscopy with the
CHO-gp160 cells incubated with the Cy3-labeled tran-
scripts (Figure 2B and C). After 2 hours of incubation,
the Cy3-labeled aptamer was selectively internalized
within the CHO-gp160 cells, but not the CHO-EE con-
trol cells (Figure 2D). To visualize the nucleus, the cells
were stained with the nuclear dye Hoechst 33342 before
incubation with the Cy3 labeled-aptamer. Figure 2C
showed that the aptamer aggregated within the cytoplasm
suggesting that the gp120 aptamers maybe enter cells
via receptor-mediated endocytosis.
Anti-gp120 aptamers inhibit HIV-1 infection of
CEM T-cells
In a previous study, investigators demonstrated that
anti-gp120 aptamers provided signiﬁcant anti-HIV
function via binding to the viral envelope and prevent-
ing viral interaction with the cellular CD4 receptor (28).
We therefore carried out an assay to determine if our
anti-gp120 aptamers would also block HIV infectivity in
cell culture. In this assay, the aptamers were incubated
with HIV-1 infected-CEM cells four days after the cells
were challenged with the virus. At diﬀerent days post-
treatment with the aptamers, aliquots of the media were
assayed for viral p24 antigen levels (Figure 3). The results
showed that the anti-gp120 aptamers (A-1 and B-68)
inhibited HIV-1 p24 production and provided somewhat
more potent inhibition than the previously published
B40t77 (28,43) (designated here as aptamer 1).
Design of anti-gp120 aptamer-siRNA chimera delivery
systems that bind and are internalized by cells
expressing HIV gp160
We next asked whether or not our newly selected aptamers
could be used as delivery vehicles for our anti-HIV siRNA
as previously reported (43). The aptamer-siRNA chimeras
(Ch A-1 and Ch B-68) (Figure 4A) were generated as pre-
viously described (43) and a two nucleotide linker (UU)
was inserted between the aptamer (A-1 or B-68) and the
Dicer substrate anti-tat/rev siRNA portion to increase
molecular ﬂexibility.
To evaluate the potency of the siRNA alone, we used
a psiCheck reporter system in which the siRNA target
was inserted in the 30-UTR of the Renilla luciferase
gene. The silencing of both the sense and antisense
orientations of the target were tested and the selectivity
ratios were calculated as a measure of the relative knock-
down eﬃciencies for each orientation (Supplementary
Figure S3). The chimeras Ch A-1 and Ch B-68, respec-
tively mediated  80% and 75% knockdown of the sense
target; however, knockdown of the anti-sense target
was much less (20–40%), indicative of good strand
selectivity (RCh A-1=3.3; RCh B-68=3.4), which is com-
parable with Ch L-1 (43).
Next, the binding aﬃnities of the chimeras for gp120
were assessed by using a gel shift assay (Figure 4B) and
Table 1. The alignment and identiﬁcation of RNA aptamers
Groups RNA Random sequences Frequency (140 clones)
I A-1 AATTGAGGGACCACGCGCTGCTTGTTGTGATAAGCAGTTTGTCGTGATGG 33 (23.6)
B-7 AATTGAGGGACCAACGCGAGGATGTGGATAGTGTGTATTTGCGTTGATGG 3
A-32 AATTGAGGGACCGTTGGTAAAAGCCGGAAATTGAGCTTTTACGGCGATGG 5
B-55 AATTGAGGTACCGCGTTATTAGGAACAAATTGGAATTCTAAACGCGATGG 2
A-24 AATAGAGGGACCCAGATATAGGCTACACGGATGATGGTGTATCTGGATGG 1
B-19 AATAGAGGAACCGTTTCAGAAGACTACAGGTTAGTCCAATGAAGCGACGG 1
B-31 AATAGAGGGACCGTGGACAATAATTTATGGTCA TTTATTGGCACGATGG 1
II A-12 AGTAGAGGAACCAAGCAATGGATGAATGCAAAAGTGTAAATGCTTGATGG 10 (7.1)
III A-9 TGAGTTTGGGTAAATTTCCGGTTTCGGTTTACTCACGAAAGATCGGTCGG 15 (10.7)
IV A-28 TAAAGGAGGGAAGGATGAGACCGCACGAAAAATATCAGCATACGTTTGTG 10 (7.1)
V A-5 GAAACTAGTTTGAATAATGGTGTAGAGGAGGGTCAATAGTTTCGTTGGTG 9 (6.4)
VI B-68 ACATAGTAATGACACGGAGGATGGAGAAAAAACAGCCATCTCTTGACGGT 2
Others Orphan sequence 48
Following the 12
th round of selection, the selected RNA pool was cloned and sequenced. After alignment of all 140 clones, six groups
of anti-gp120 aptamers were identiﬁed. Only the random sequences of the aptamer core regions (50–30) are indicated. The conserved
sequences in the group I and II were underlined. Isolates occurring with multiple frequency are speciﬁed. Values are given as n (%).
Nucleic Acids Research,2009, Vol.37, No. 9 3099ﬂow cytometry (Figure 4C). These data indicate that the
chimeras maintain approximately the same binding aﬃ-
nities as the aptamers alone. To determine if the bound
chimeras were internalized in the gp160 expressing cells,
we carried out Z-axis confocal microscopy with the CHO-
gp160 cells incubated with Cy3-labeled transcripts. The
time-course images (Supplementary Figure S4) showed
that Cy3-labeled chimera Ch A-1 was successfully inter-
nalized into the cytoplasm of cells. To visualize the
nucleus, the cells were stained with the nuclear dye
Hoechst 33342 before incubation with Cy3-RNA. As
expected, no uptake of the chimera was observed with
the CHO-EE control cells (data not presented).
Anti-gp120 aptamer-siRNA chimeras inhibit HIV-1
infection of CEM T-cells and human PBMCs
To verify the anti-HIV activity of the chimeras in inhibit-
ing HIV-1 replication, we carried out the HIV-1 challenge
assays as previously described (43). In this assay, the
experimental RNAs were incubated with HIV-1 IIIB
infected-CEM cells or HIV-1 NL4-3 infected human
PBMCs. The results of p24 antigen analyses (Figure 5A
and B) showed that each of the aptamers and chimeras
inhibited p24 production, but the strongest inhibition
was observed with the chimera Ch A-1 treatment. In
particular, A-1 and Ch A-1 showed stronger suppression
of HIV-1 than aptamer 1 and Ch L-1 previous reported
(43) at 7 and 9 days of posttreatment in PBMCs.
To conﬁrm that the siRNA component was functioning
along with the aptamer, following internalization of
the Ch A-1 chimera in infected cells, we also evaluated
the relative levels of inhibition of tat/rev gene expression.
Aptamers or chimeras were added directly to media
containing infected human PBMCs. After 7 days of post-
treatment, treated cells were harvested, the total RNA
was extracted and the expression level of tat/rev mRNA
was determined by quantitative RT–PCR expression
assays. We ﬁnd that the treatment of infected cells
with the chimeras is able to induce silencing of the
tat/rev gene, while the aptamer alone did not aﬀect
tat/rev gene expression (Figure 5C). These results pro-
vide further support that the aptamer delivered siRNA
triggers RNAi.
Design of anti-gp120 aptamer-stick-siRNA delivery
systems that bind and are internalized by cells
expressing HIV gp160
An ideal aptamer chimera for use against HIV-1 would
have the capacity for easily combining diﬀerent siRNAs
to avert the viral escape mutants. A new delivery system
design based on the A-1 aptamer was constructed which
facilitates the ready exchange of siRNAs associated
with the aptamer (Figure 6A). In this design format the
aptamer and siRNAs are linked via ‘stick’ sequences
consisting of 16nt at the aptamer 30-end which are com-
plementary to 16 bases on one of the two siRNA strands.
After a simple incubation of the aptamer and the pre-
formed siRNA with this ‘sticky’ sequence, a stable base-
paired chimera is formed (Figure 6A and Supplementary
Figure S5). In the present design, all the RNA components
are chemically synthesized. The siRNA portion targets
the HIV-1 tat/rev common exon sequence. Seven three-
carbon atoms (C3) as linker was put between RNA
strand and stick sequence in order to provide molecular
ﬂexibility, not interfering aptamer correct folding.
Aptamer A-1 with ‘sticky’ end (A-1-stick) and sense
strand of siRNA were 20-ﬂuoropyridinium modiﬁed,
which enhance their RNase resistance in mouse serum
(data not shown).
The psiCheck reporter system was used to evaluate
the RNAi potencies and strand selectivity of the
A
B
Figure 1. Binding activity assay and predicted secondary structure of
selected individual aptamers against HIV-1BaL gp120. (A) Binding curve
from a gel shift assay. The 50-end P
32-labeled individual aptamers
were incubated with the increasing amounts of gp120 protein. The
binding reaction mixtures were analyzed by a gel mobility shift assay.
Aptamer A-1 and B-68 showed the best binding aﬃnity with the target
protein. (B) The predicated secondary structures of the anti-gp120
aptamer A-1 and B-68 as predicted by QuickFOLD and the calculated
Kd determinations are indicated. Data represent the average of four
replicates.
3100 Nucleic Acids Research, 2009, Vol. 37,No. 9aptamer–stick–siRNA system. The gene silencing of both
the sense (corresponding to the mRNA) and the anti-
sense strands were tested independently (Supplementary
Figure S6). As expected, N-1 and N-2 down-regulated
the sense target expression and had a good strand selec-
tivity (RN-1=4.0; RN-2=2.1). From these results we
conclude that the siRNA component of the ‘stick’ apta-
mer–siRNA chimeras mediated the desired target knock-
down and exhibits a strand bias in favor of the desired
anti-tat/rev guide sequence. Interestingly, the N-1 design
mediated more eﬃcient knockdown of the sense target
( 85%) than the N-2 design ( 55%), suggesting that
more potent Dicer-cleavage might be generated from the
N-1 design.
We also carried out gel mobility shift assays to moni-
tor the gp120 binding capabilities of these chemically
synthesized chimeras and observed binding to the tar-
get protein with nanomolar dissociation constants
(Figure 6B). These synthetic ‘stick’ chimeras selectively
bind to cells expressing gp160 (Figure 6C) and are
internalized into the cytoplasm (Figure 6D). The live-cell
confocal images demonstrated that N-1 containing a
A
C
D
B
Figure 2. Cell-type speciﬁc binding and uptake studies of aptamers. (A) Cell surface binding of Cy3-labeled RNAs was assessed by ﬂow cytometry.
Cy3-labeled RNAs were tested for binding to CHO-gp160 cells and CHO-EE control cells. The selected aptamers showed cell-type speciﬁc binding
aﬃnity. The 2nd RNA pool and irrelevant RNAs were used as negative controls. Data represent the average of three replicates. (B) Internalization
analysis. CHO-gp160 cells were grown in 35mm plates and incubated with a 100nM concentration of Cy3-labeled A-1 in culture media for real-time
live-cell-confocal microscopy analysis. The images were collected at 15min intervals using 40  magniﬁcation. (C,D) Localization analysis. CHO-
gp160 cells (C) and CHO-EE control cells (D) were grown in 35mm plates. Before incubation with 100nM of Cy3-labeled A-1, cells were stained
with Hoechst 33342 (nuclear dye for live cells) and then analyzed using real-time confocal microscopy.
Nucleic Acids Research,2009, Vol.37, No. 9 310150-end Cy3-labeled sense strand successfully delivers
siRNA into the cytoplasm of gp160 expressing cells.
Aptamer-based delivery systems are processed by Dicer
To determine whether or not human Dicer can process
the siRNA portion of these chimeras, either the sense or
antisense strands were end-labeled with g-
32P-ATP and
subsequently used in formation of the chimeras
(Figure 7A). The chimeras were incubated with recombi-
nant human Dicer and the cleavage products were
analyzed by denaturing gel electrophoresis. The size
of the P
32 labeled cleavage product(s) indicates from
which direction Dicer enters the siRNA and cleaves
(Figure 7A and Supplementary Figure S7). When
chimera Ch A-1 was incubated with the human Dicer
and the
32P-label was placed on the 50-end of the antisense
strand (Figure 7A and B), we observed that the pri-
mary processing takes place via Dicer entry from the
opposite side of the aptamer since the majority of the
32P-labeled resides in the 21- to 23-mer sized product
as opposed to the shorter 6nt product, which derives
from Dicer entry on the aptamer side of the duplex.
For the N-1 and N-2 ‘stick’ aptamer chimeras, Dicer
only processes these from side containing the 2 base
30 overhang since only a single species of
32P-labeled
product is seen regardless of whether the label is at
the 50-end of the sense or antisense strand (Figure 7B).
Since the positions of the sense and antisense strands
diﬀer between N-1 and N-2 with respect to the two base
30 overhang, Dicer cleavage results in predictably diﬀer-
ent 21–23 siRNA products from these two conﬁgurations
(Supplementary Figure S7) which can have diﬀerent
potencies.
Anti-gp120 aptamer-stick-siRNA system inhibits
HIV-1 infection in primary human PBMCs
In order to test the anti-HIV activity of the aptamer–
stick–siRNAs for their inhibition of HIV-1 replication,
we carried out HIV-1 challenge assays as described
above. The experimental RNAs were incubated with
HIV-1 Bal infected human PBMCs and over a period of
several days the HIV encoded p24 antigen levels were mea-
sured (Figure 8A). These results veriﬁed that each of the
A
B
C
Figure 4. The design and binding activity of the aptamer-siRNA deliv-
ery system. (A) Schematic aptamer-siRNA chimeric RNAs: the region
of the anti-gp120 aptamer is responsible for binding to gp120 and the
siRNA is targeting a common exon of HIV-1 tat/rev. A linker (UU)
between the aptamer and siRNA is indicated in green. (B) The apta-
mer-siRNA chimeric RNAs that have comparable Kd values as well
as parental aptamers speciﬁcally bind the HIVBaL gp120 protein.
Data represent the average of three replicates. (C) Cell-type speciﬁc
binding studies of aptamers. Cy3-labeled RNAs were tested for binding
to CHO-gp160 cells and CHO-EE control cells. Cell surface bindings
of Cy3-labeled RNAs were assessed by ﬂow cytometry. The selected
aptamers showed cell-type speciﬁc binding aﬃnity. The 2
nd RNA pool
and irrelevant RNA were used as negative controls. Data represent the
average of two replicates.
Figure 3. The selected anti-gp120 aptamers inhibit HIV-1 replication in
cells previously infected with HIV-1. The 1.5 10
4 HIV-1 infected
CEM cells and 3.5 10
4 uninfected CEM cells were incubated at
378C with the various experimental RNAs at a ﬁnal concentration of
400nM. The culture supernatants were collected at diﬀerent time points
following addition of the aptamers (3d, 5d, 7d, 9d and 11d) for p24
antigen analyses. Data represent the average of triplicate measurements
of p24.
3102 Nucleic Acids Research, 2009, Vol. 37,No. 9aptamer and aptamer–stick–siRNA combinations inhib-
ited p24 production. As we have previously observed,
the best suppression of HIV replication derived from the
chimeric aptamer–siRNAs Ch A-1 and N-1. We also car-
ried out qRT–PCR to evaluate the down-regulation of
tat/rev gene expression to conﬁrm the siRNA function
following internalization within infected PBMCs. After 7
days of treatment, treated cells were harvested, the
total RNA was extracted and the extent of tat/rev gene
inhibition was determined by quantitative RT-PCR.
The N-1 chimera inhibited tat/rev expression by  50%
relative to the controls, whereas the aptamer alone
did not aﬀect the levels of tat/rev gene expression
(Figure 8B). For comparison, N-2 gave somewhat less
target knockdown than the N-1 and Ch A-1 chimeras.
An ideal chimeric aptamer-siRNA delivery system tar-
geting HIV would have the capacity for combining vari-
ous siRNAs to avert viral escape mutants. HIV-1 exploits
multiple host proteins during infection. It has been
demonstrated that more than 250 HIV-dependency
factors (HDFs) are required by HIV infection (48).
These proteins participate in a broad array of cellular
functions and implicate new pathways in the viral life
cycle. Therefore, we took advantage of the ‘stick’ bridge
to tether the anti-gp120 aptamer with diﬀerent siRNA
portions targeting HIV-1 dependency factors. The exam-
ples shown (Figure 9) include TNPO3 (known as trans-
portin 3, a karyopherin required for viral integration) and
CD4 (the primary receptor for viral entry).
The HIV-1 challenge assays were performed as
described above. The experimental RNAs were incubated
with HIV-1 IIIB infected CEM cells and the HIV encoded
p24 antigen levels were measured (Figure 9A). In all cases,
the aptamer–stick–siRNA combinations (Tat/rev N-1,
TNPO3N-1, CD4N-2 and the siRNA-cocktails) pro-
vided more potent inhibition than the aptamer alone.
Knockdown of target gene expression was further evalu-
ated by qRT-PCR, which conﬁrmed for each combination
that the siRNAs were functioning following internaliza-
tion in the HIV infected CEM cells. The CD4N-2 chimera
inhibited CD4 expression by  75% relative to the con-
trols, whereas the aptamer alone did not aﬀect the levels
of CD4 gene expression (Figure 9B). The tat/rev N-1
and TNPO3N-1 also gave  50% silencing for the corre-
sponding target genes. For comparison, the three siRNA-
cocktails gave somewhat less indvidual target knockdown
than the single siRNA chimera, suggesting that there
may be competition for RISC loading between the various
siRNAs. We have not yet optimized the amounts of each
individual chimera in the mix required to minimize this
type of competition.
The aptamer-based delivery system does not trigger
a type I interferon response
It has been reported previously that siRNAs delivered by
liposomes or polyplex reagents can non-speciﬁcally acti-
vate inﬂammatory cytokine production (TNFa, IL-6 and
IL-12) as well as IFN responsive genes, which in turn can
trigger cellular toxicity. We therefore assessed the induc-
tion of type I interferon regulated gene expression by our
anti-gp120 aptamer-based siRNA delivery system using
quantitative RT-PCR expression assays. We used IFN-a
as a positive control to conﬁrm up regulation of p56
(CDKL2) and OAS1 gene expression. The treatment of
HIV-1 infected CEM cells (data not shown) with the
chimeras did not induce type I IFN responses. Similar
results were obtained using HIV infected primary human
PBMCs treated with these chimeric aptamer–siRNAs
A
B
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Figure 5. Dual inhibition of HIV-1 infection mediated by aptamer-
siRNA chimeras. Both anti-gp120 aptamer and aptamer-siRNA
chimeras neutralized HIV-1 infection in (A) CEM cells (IIIB strain)
and (B) human PBMCs (NL4-3 strain) culture, respectively. Data
represent the average of triplicate measurements of p24. The chimeras
(Ch A-1 and Ch B-68) showed stronger inhibition than aptamer alone
indicating that (C) the siRNA delivered by the aptamers down-
regulated Tat/rev gene expression in the PBMCs. Data represent the
average of three replicates.
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Figure 6. Cell-type speciﬁc aptamer-stick-siRNA delivery system. (A) Schematic aptamer-stick-siRNA system (N-1 and N-2). The anti-gp120 aptamer
A-1 and the 27mer siRNA targeting HIV-1 tat/rev are shown. The siRNA is linked to the aptamer portion via the ‘‘stick’’ sequence which consists of
16nt appended to the aptamer 30-end allowing complementary interaction of one of the two siRNA strands with the aptamer. After a simple
incubation of the A-1-stick and NS-1 or NS-2 siRNA conﬁgurations, they form stable base-pairing. A linker of seven three-carbons between the
aptamer RNA and the stick portion is used to avoid steric interaction of the stick with the aptamer. (B) The aptamer-stick-siRNA system (N-1 and
N-2) has comparable Kd values to the aptamer A-1 alone in binding assays with the HIVBal gp120 protein. Data represent the average of two
replicates. (C) Cell-type speciﬁc binding studies of aptamer-stick-siRNA. Cy3-labeled RNAs were tested for binding to CHO-gp160 cells and CHO-
EE control cells. Binding of the Cy3-labeled RNAs was assessed by ﬂow cytometry. The selected aptamers show cell-type speciﬁc binding aﬃnities. A
27 mer duplex RNA (NS-3) with a 50-Cy3-labelled sense strand is used as a negative control. Data represent the average of two replicates. (D)
Internalization and intracellular localization analyses. CHO-gp160 cells were grown in 35mm plates and incubated in culture medium with a 100nM
concentration of N-1 containing a 50-Cy3-labeled sense strand for real-time live-cell confocal microscopy analysis as previously described. After
overnight incubation, cells were stained with Hoechst 33342 (nuclear dye for live cells) and then analyzed by confocal microscopy.
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Figure 7. In vitro Dicer processing. (A) Dicer cleavage of 50-end P
32 sense or antisense labeled RNAs. The RNA strands were annealed with equal
molar equivalents of 50-end P
32-labeled complementary RNA strands. (B) The P
32-labeled RNAs were marked with asterisks. The cleavage products
or uncleaved, denatured strands were visualized following 20% denaturing PAGE. According to path of Dicer entry diﬀerent cleavage products were
observed. For example, the 50-end P
32-labeled antisense N-1 and 50-P
32 sense strand N-1 was cleaved into two products, one of which is 21–23nt and
the other a lower abundance 6nt fragment. The results obtain suggest that Dicer preferentially enters N-1 using the 30-end of the sense strand.
Nucleic Acids Research,2009, Vol.37, No. 9 3105(Supplementary Figure S8), suggesting that the gp120
mediated internalization of the chimeras does not trigger
toxic IFN responses.
DISCUSSION
Nucleic acid aptamers with binding aﬃnities in the low
to mid-nanomolar range have been utilized for ﬂexible
applications ranging from diagnostic to therapeutic assay
formats. Moreover, aptamers that target speciﬁc cell sur-
face proteins are employed as delivery molecules to target
a distinct cell type, hence reducing oﬀ-target eﬀects or
other unwanted side eﬀects. We have capitalized on the
exquisite speciﬁcity of a gp120 aptamer to deliver anti-
HIV siRNAs into HIV infected cells with the net result
that the replication and spread of HIV is strongly inhibited
by the combined action of the aptamer and a siRNA
targeting the tat/rev common exon of HIV-1. Therefore,
the anti-gp120 aptamers can function both as antiviral
agents and as siRNA delivery reagents.
It is highly desirable to generate new aptamers to
expand their diversity for in vivo applications. In a thera-
peutic setting, anti-gp120 aptamers and various siRNAs
targeting diﬀerent genes may need to be interchanged to
avert viral resistance. In the present work, a series of
new 20-F substituted RNA aptamers that speciﬁcally
bind to the HIV-1BaL gp120 protein with nanomolar aﬃ-
nity were successfully isolated from an 81nt RNA library
via SELEX (Systematic Evolution of Ligands by
EXponential enrichment). The selected aptamers are
able to speciﬁcally bind gp120 and are internalized into
cells expressing the HIV envelope. We observe an aggre-
gation of aptamer within the cytoplasm as revealed by
confocal microscopy, suggesting that the aptamers are
internalized by gp120-mediated endocytosis. In addition,
these aptamers have been shown to inhibit several dif-
ferent HIV-1 strains, indicating that anti-gp120 aptamers
that inhibit the initial step of HIV-1 entry by blocking
the binding of the gp120 and CD4 receptor may be
useful in HIV-1 therapeutic applications. Compared with
the previously published B40t77 aptamer that was
selected against the HIV-1BaL gp120 protein through
BIAcore biosensor chip-based SELEX, our selected
aptamers show somewhat better inhibitory activity. The
fact that B40t77 did not bind with our target protein
suggests that the diﬀerent sources of target and selection
methods can aﬀect the aptamer-target protein binding
epitopes.
A
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Figure 8. Dual inhibition on HIV-1 infection mediated by aptamer-based siRNA delivery system. (A) Both anti-gp120 aptamer, aptamer-siRNA
chimeras (Ch A-1) and aptamer-stick-siRNA (N-1 and N-2) neutralize HIV-1 Bal infection in PBMCs. The chimeras Ch A-1, N-1 and N-2 were
more potent inhibitors than the respective aptamers alone. Data represent the average of triplicate measurements of p24. (B) The siRNA delivered by
aptamers down-regulates tat/rev gene expression in human PBMCs. Data represent the average of three replicates.
3106 Nucleic Acids Research, 2009, Vol. 37,No. 9On the basis of our previous results, two kinds of dual
inhibitory functional anti-gp120 aptamer-based delivery
systems were constructed and evaluated for HIV-1 inhibi-
tion. In the ﬁrst design, we cotranscribed the aptamer–
siRNA sense single strand, followed by annealing of
the complementary siRNA antisense strand to complete
the chimeric molecule. Speciﬁcally, the secondary design
is a worthy point of discussion. A new anti-gp120
aptamer–stick–siRNA delivery system has been designed
which allows mixing new siRNAs with the same aptamer,
which could ultimately be useful for minimizing viral
escape mutants. Both the aptamer and siRNA portions
are chemically synthesized and subsequently annealed
via a complementary 16-nt ‘stick’ sequence which forms
a stable base-pair via the ‘sticky’ bridge. The linker, seven
sets of three-carbon atoms (C3), between the RNA and
the stick end provides molecular ﬂexibility and minimizes
steric hindrance which could impede annealing of the two
RNAs. These design strategies not only guarantee tight
conjugation of the aptamer with the siRNA portion, but
also do not interfere with correct folding of the aptamer
and the Dicer processing of the siRNA. Most importantly,
since this kind of design is quickly assembled from
two chemically synthesized RNA portions, each portion
is easily changed to avert viral resistance. So far, the
chemical synthesis of long RNAs is limited by the length
and backbone modiﬁcations of the RNAs. Using the
‘sticky bridge’ strategy, we have been able to chemically
synthesize a 20-ﬂuoropyrimidine modiﬁed aptamer (81nt
plus 16-base bridge) separately from the 27bp (plus 16
base bridge) siRNA in milligram scale, followed by
in vitro joining of the two RNAs. This attractive ‘sticky’
A
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Figure 9. The HIV-1 inhibition mediated by the various siRNAs delivered using the ‘stick’ aptamer system. (A) Three diﬀerent siRNAs which target
the HIV-1 Tat/rev, human CD4 receptor and HIV-1 dependency factor TNPO3 RNAs, were annealed to aptamer A-1 via the ‘stick’ bridge. The
resulting aptamer-stick-siRNAs (Tat/rev N-1, TNPO3N-1 and CD4N-2) neutralized HIV-1 infection in CEM cell culture, providing more potent
inhibition than the aptamer alone. The combination of three siRNAs also suppressed the HIV-1 replication. Data represent the average of triplicate
measurements of p24. (B) The siRNAs delivered by aptamers down-regulates target gene expression in the HIV infected CEM cells (HIV-1 tat/rev,
TNPO3 and CD4). Data represent the average of three replicates.
Nucleic Acids Research,2009, Vol.37, No. 9 3107bridge-based approach can potentially be used for mixing
diﬀerent siRNAs with a single aptamer to multiplex tar-
get down regulation, and in the case of HIV infection, to
avert resistance to the siRNA component.
We demonstrate that our delivery systems speciﬁcally
bind to the surface of cells expressing gp160 and are inter-
nalized, allowing functional processing of the siRNA
into RISC, resulting in speciﬁc inhibition of HIV-1 repli-
cation and infectivity in cell culture. Both of the
anti-gp120-based siRNA delivery systems serve as dual
function inhibitors and therefore provide greater eﬃcacy
than either the aptamer or siRNA applied alone.
Interestingly, even though our designs (Ch A-1, N-1 and
N-2) are able to down-regulate the target expression and
show good strand selectivity, their RNAi potencies are
diﬀerent. Previous studies of Dicer substrate siRNAs
(49,50) used substrates in which Dicer entry on the blunt
end of the DsiRNAs was completely blocked by placing
two deoxy nucleotides at the 30-end of the desired passen-
ger strand, creating an absolute polarity for Dicer entry
from the two base 30 overhang. The present studies did
not employ deoxys so entry from the blunt end of the
Ch A-1 siRNA takes place relatively eﬃciently relative
to the entry from the 2 base 30 overhang, which is adja-
cent to the aptamer that creates a steric hindrance for
Dicer entry (Figure 7B). Also, in contrast to our previous
observations, (49,50) the preference for guide strand
selection in our chimeras does not necessarily favour the
strand with the two base 30 overhang (Supplementary
Figures S6 and S7), since the more potent conﬁguration
N-1 has the guide strand positioned with the 50-end at
the side of Dicer entry. In this context it should be
noted that the strand selectivity of N-1 is not as good as
that of N-2 (Supplementary Figure S6). The diﬀerence in
potency between N-1 and N-2 most likely resides in the
species of 21- to 23-mer produced, which diﬀer between
the two forms. Interestingly, Dicer does not process the
‘stick’ aptamer siRNAs at all from the blunt end side as
it does with the Ch A-1. We attribute this to the lack of a
free 30OH in these chimeras, in which the end of the
siRNA is covalently attached to the ‘stick’ sequence
which in turn forms a 20OMe modiﬁed duplex with the
aptamer. The 20OMe backbone modiﬁcations throughout
the ‘stick’ also block Dicer cleavage (51). Since the
strand selectivity of Dicer generally favors the strand
with the 2 base 30 overhang (49,50), it is important to
design the Dicer substrates such that a potent siRNA
against the desired target generated from the cleavage
event. This will minimize the oﬀ target potential of the
passenger strand.
In summary, we have demonstrated that the anti-gp120
aptamers not only provide a potential new drug therapy
approach for combating HIV infection, but also act as
delivery vehicles for siRNAs and perhaps other small
RNA inhibitors. The ‘sticky’ bridge-base approach oﬀers
a major advantage in both chemical synthesis and the
opportunity to mix and match the aptamer with diﬀerent
siRNAs in a non-covalent fashion. For HIV clinical
applications, the mixing approach may be a requirement
for averting viral escape mutants.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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